Beyond vaccines, what are scientists developing to respond to the new crown outbreak?

Among the committee's recommendations to the World Health Organization (WHO) and States parties, accelerating research and promoting access to diagnostic tools, treatments and vaccines is one of the most important.
since the outbreak of COVID-19, the development of new coronavirus vaccines has been ongoing at an unprecedented rate, and several vaccines are now in the process of entering Phase 3 clinical trials.
However, even if clinical trials prove that vaccines are safe and effective, we still need coVID-19 therapies, tests, and public health measures to control further development of the outbreak and save patients' lives before they can protect the world's people.
, let's take a look at the latest developments in biopharmaceutical companies beyond vaccines.
to improve the immunity of vulnerable groups, Lilly initiated a phase 3 preventive study of the antibody, Eli Lilly and Company today announced the launch of phase 3 clinical trial BLAZE-2.
the effects of the new coronavirus and COVID-19 in the new coronavirus, developed jointly with AbCellera, and the antibody LY-CoV555.
clinical trial will be conducted in nursing homes across the United States, with the elderly and health care workers in nursing homes.
the new crown vaccine, one of the most vulnerable groups in the new crown outbreak, is likely to trigger a weaker immune response for older people.
, the development of other means to enhance the immunity of the elderly is an important part of controlling the new crown outbreak and saving patients' lives.
LY-CoV555 is a medium antibody developed jointly by Lilly and AbCellera.
because antibodies have a long half-life in the body, after one infusion, they can remain in human memory for weeks or even months, providing passive immunity to the people receiving the injection.
is especially important for people who may not be able to develop effective immune protection through vaccination (immune system deficiencies or the elderly).
This is a unique clinical study, and Lilly, in partnership with the National Institute of Allergy and Infectious Diseases (NIAID), can provide on-site infusion services and services for clinical trials in nursing homes across the country by transforming motorhomes (RVs) and trailers into mobile clinical trial sites.
the trial will register high-risk residents and staff in nursing homes with recent cases of COVID-19 to assess whether a dose of LY-CoV555 reduces the rate of new coronavirus infections within four weeks and whether a dose reduces COVID-19-related complications within eight weeks.
is expected to recruit up to 2,400 participants.
"COVID-19 has had a devastating effect on nursing home residents.
we are developing drugs as soon as possible to stop the spread of the virus to these vulnerable individuals.
Though clinical trials are not easy in this situation, we are meeting the challenge of helping those who need us most," said Dr. Daniel Skovronsky, Lilly's Chief Scientific Officer and President of Lilly Research Labs.
" Takeda, AbbVie, and Amgen conducted adaptive platform trials to test a variety of COVID-19 therapies Today, AbbVie, Amgen, and Takeda, members of the COVID Research and Development Alliance, announced that the first patient, the adaptive platform trial called I-SPY COVID, was registered.
this clinical trial will evaluate the efficacy of CCR2/CCR5 dual antagonist cenicriviroc, PDE4 inhibitor Otezla (apremilast), and anti-inflammatory peptide B2 recipient antagonist Fiazyr (icatibant) in severe hospitalized COVID-19 patients requiring high-flow oxygen therapy.
these treatments are based on their potential effects on the immune system response in patients with COVID-19 who need breathing support.
about 10-15% of COVID-19 patients develop acute respiratory distress syndrome (ARDS), and 60% of patients who enter the ICU require an average of two weeks of breathing support, and it is estimated that half of them will not survive.
Otezla may suppress inflammation caused by the immune response; Firazyr may improve peptide-driven pulmonary edema; and cenicriviroc may help reduce the severity of ARDS in severe COVID-19 patients by blocking the transport of monocytes to tissues.
the study is the product of a collaboration between members of the COVID Research and Development Alliance and Quantum Leap Healthcare, as well as the FDA.
it uses Quantum Leap's adaptive platform trial design to improve the efficiency of clinical trials by minimizing the number of people involved in clinical trials and the time it takes to evaluate potential therapies.
"Patients with serious illnesses in hospitals can't wait long, we desperately need treatment options, and I'm proud to join the COVID research and development alliance with AbbVie, Amson, and other companies and launch key platform trials like I-SPY," said Dr. Andy Plump, co-founder of the COVID Research and Development Alliance and president of Takeda Research and Development.
with experts from different companies and industries, it is hoped that promising clinical trials of in-study therapies will be accelerated to identify early treatments that have an effect on this serious disease.
" NIH has selected seven innovative new crown tests and invested nearly $250 million to expand production, after the National Institutes of Health (NIH) announced that its Rapid Acceleration Diagnostics , RADx program has invested nearly $250 million in seven biomedical diagnostics companies to support the further development and expansion of a range of COVID-19 tests based on laboratory or bedside testing.
RADx process schematic (Photo: Credit, NIH) RADx project was launched on April 29 this year to rapidly develop testing tools for COVID-19.
received more than 650 applications for the project, and after several rounds of evaluation by hundreds of experts, RADx selected seven companies to test expanded production and plans to launch through RADx.
tests have not yet been approved by the FDA.
biotech companies that have reached this milestone are: Point-of-Care Tests Mesa Biotech, San Diego's Accula SARS-CoV-2, using handheld RT-PCR devices and compact disposable test boxes to detect viral RNA at the point of care.
can be read from a removable test card in 30 minutes.
Quidel, San Diego Quidel Sofia SARS antigen FIA kit is a side-flow immunoassay used with Sofia and Sofia2 analyzers for bedside testing, such as in a doctor's office or pharmacy.
has thousands of Quidel analyzers in the U.S., and the U.S. Department of Health and Human Services (HHS) has identified the technology for use in nursing homes.
analyzer gives electronic results within 15 minutes.
Talis Biomedical, Menlo Park Talis One COVID-19 Bedside Detection is a multi-test kit that works with portable Talis One instruments.
the test detects the new coronavirus through the iso-temperature amplification and optical detection system of viral RNA and returns the results within 30 minutes.
laboratory tests Ginkgo Bioworks, Boston Ginkgo Bioworks uses automated and high-volume next-generation sequencing technology to detect samples on a large scale, processing tens of thousands of tests simultaneously.
Ginkgo Bioworks will work with schools, public or private companies and local patient groups to provide end-to-end sample collection and report results within 24-48 hours.
Helix, San Mateo Helix will ship standardized kits for bulk nose swabs to public health departments, healthcare systems and other customers.
can take tens of thousands of samples at once and process them within 24-48 hours.
a combination of complex automated processes and next-generation sequencing technology, Helix expects to process up to 50,000 samples per day by the end of September 2020 and 100,000 samples per day by the end of the year.
Fluidgm, South San Francisco Each BioMark HD microflow platform has the ability to process thousands of new coronavirus PCR tests every day, mainly using saliva samples.
There are already many Fluidigm instruments in clinical and research laboratories across the United States that will provide tens to hundreds of thousands of new tests per day by the fall of 2020 by expanding the deployment of its advanced integrated microflower chips.
Mammoth Biosciences, South San Francisco Mammoth Biosciences' SARS-CoV-2 DETECTR test uses CRISPR technology to provide simpler workflows and faster turnaround times than traditional laboratory PCR testing.
high-volume solution can multiply the testing capabilities of commercial laboratories.
Dr Bruce J. Tromberg, director of the National Institute of Biomedical Imaging and Bioengineering (NIBIB), said: "These tests and new technologies emerging in the RADx pipeline will not only guide patient care and public health measures to control the spread of the virus, but will also equip us with better weapons to deal with future pathogens and diseases."
" References: s1. Lilly Initiates Phase 3 Trial of LY-CoV555 for Prevention of COVID-19 Long at-Term Care Careies in Partnership with National Institute of Allergy and Analytic Diseases (NIAID). Retrieved August 3, 2020, from .2 Members of the COVID R and D Alliance and LeapIng Healthcare First Patients in I-SPY COVID Trial. Retrieved August 3, 2020, from the NIH delivering new COVID-19 testing technologies to meet U.S. demand. Retrieved August 3, 2020, from.